StockNews.com Lowers Koninklijke Philips (NYSE:PHG) to Hold

Koninklijke Philips (NYSE:PHG) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other analysts have also issued reports on the stock. Sanford C. Bernstein upgraded shares of Koninklijke Philips from a “market perform” rating to an “outperform” rating in a research report on Monday, May 13th. UBS Group upgraded shares of Koninklijke Philips from a “sell” rating to a “neutral” rating in a research report on Tuesday, April 30th. BNP Paribas upgraded Koninklijke Philips from an “underperform” rating to a “neutral” rating in a report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. upgraded shares of Koninklijke Philips from an “underweight” rating to a “neutral” rating in a research report on Tuesday, April 30th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $19.00.

Koninklijke Philips Stock Up 3.0 %

Koninklijke Philips stock traded up $0.75 during mid-day trading on Thursday, hitting $26.03. 514,976 shares of the company’s stock were exchanged, compared to its average volume of 669,659. Koninklijke Philips has a 1-year low of $17.75 and a 1-year high of $29.44. The stock has a 50 day moving average of $26.27 and a two-hundred day moving average of $23.11. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58. The stock has a market cap of $23.59 billion, a P/E ratio of -27.11, a P/E/G ratio of 0.92 and a beta of 0.72.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings data on Monday, April 29th. The technology company reported $0.28 earnings per share for the quarter. Koninklijke Philips had a negative net margin of 4.41% and a positive return on equity of 9.82%. The business had revenue of $4.49 billion during the quarter. As a group, analysts anticipate that Koninklijke Philips will post 1.51 EPS for the current fiscal year.

Institutional Trading of Koninklijke Philips

Institutional investors and hedge funds have recently made changes to their positions in the business. Mondrian Investment Partners LTD boosted its stake in Koninklijke Philips by 45.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 9,553,058 shares of the technology company’s stock worth $191,061,000 after acquiring an additional 2,971,008 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Koninklijke Philips by 361.7% in the first quarter. Jane Street Group LLC now owns 629,136 shares of the technology company’s stock worth $12,583,000 after acquiring an additional 492,881 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Koninklijke Philips by 85.6% in the fourth quarter. Russell Investments Group Ltd. now owns 1,033,823 shares of the technology company’s stock valued at $24,119,000 after buying an additional 476,907 shares in the last quarter. Brandes Investment Partners LP boosted its stake in Koninklijke Philips by 48.7% in the 4th quarter. Brandes Investment Partners LP now owns 1,285,935 shares of the technology company’s stock worth $30,001,000 after purchasing an additional 421,055 shares during the period. Finally, OLD Mission Capital LLC boosted its position in shares of Koninklijke Philips by 434.9% during the fourth quarter. OLD Mission Capital LLC now owns 434,282 shares of the technology company’s stock worth $10,132,000 after buying an additional 353,096 shares during the period. Institutional investors own 13.67% of the company’s stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.